Circio And United Immunity Collaborate To Advance In Vivo CAR-M Therapy Using Circular RNA Technology

Circio Holding ASA has announced a research collaboration with United Immunity Co., Ltd. to explore in vivo CAR-Macrophage (CAR-M) therapy. The partnership will focus on combining Circio’s circular RNA technology with United Immunity’s delivery platform to advance novel therapeutic approaches.

Circio’s proprietary circVec circular RNA expression platform has previously shown the ability to enhance and prolong gene expression in gene and cell therapies. Under the collaboration, United Immunity will evaluate whether circVec can be effectively delivered via its P-LNP platform to target myeloid immune cells and extend the therapeutic payload's activity.

“In vivo cell therapy is currently an extremely active development field highlighted by several recent strategic transactions, including two circular RNA companies” said Dr. Victor Levitsky, CSO of Circio. “United Immunity has a very interesting and clearly differentiated drug delivery approach targeting immune cells in the tumor, which we mutually believe can act synergistically with Circio´s circVec circular RNA expression technology. If the combination works as expected, the collaboration may lead to the generation of a joint platform for completely novel CAR-M in vivo therapies.”

The goal of this joint research is to assess the potential of integrating both technologies for in vivo CAR-M therapies, which are being explored as innovative treatments for cancer, fibrosis, and autoimmune diseases.